| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 10/14/2004 | US20040202720 Delivery of immune response modifier compounds using metal-containing particulate support materials |
| 10/14/2004 | US20040202719 cross-linked polymer encapsulating the therapeutic agent; degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades. |
| 10/14/2004 | US20040202718 compressible controlled release core, swellable polymers one of which is anionic, and an excipient(s) that improves compressibility; an immediate release composition comprising long-acting sulfonyl urea (glimepiride) and controlled release composition comprising biguanide (metformin) |
| 10/14/2004 | US20040202717 Abuse-resistant oral dosage forms and method of use thereof |
| 10/14/2004 | US20040202716 Composition |
| 10/14/2004 | US20040202715 Intraoral quickly disintegrating tablets |
| 10/14/2004 | US20040202714 Oral pharmaceutical composition |
| 10/14/2004 | US20040202712 Emulsion vehicle for poorly soluble drugs |
| 10/14/2004 | US20040202711 Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
| 10/14/2004 | US20040202710 preferably diethylene glycol monoethyl ether, diethylene glycol dimethyl ether, one of the butanediols, tetrahydrofurfuryl alcohol, dipropylene glycol, and/or propylene glycol; transdermal therapeutic system |
| 10/14/2004 | US20040202709 Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery therof |
| 10/14/2004 | US20040202708 adjacent to the reservoir comprising a releasably stored drug dosage; barrier may be indium tinoxide, aluminum oxide, silicon oxide, aluminum-silicon-oxide, aluminum-silicon-nitride, or aluminum-silicon-oxy-nitride |
| 10/14/2004 | US20040202707 self-adhesive matrix based on polysiloxanes and containing capsaicin contains liquid microreservoir droplets of an amphiphilic solvent, in which the capsaicin is dissolved |
| 10/14/2004 | US20040202706 Methods of administering a dermatological agent to a subject |
| 10/14/2004 | US20040202705 including as a permeation enhancer fatty acids, fatty acid esters, fatty alcohols, amides, pyrrolidones, glycerol triesters, and/or terpenes and their salts; provides a huperzine blood plasma level of 0.1 - 30 mg/ml |
| 10/14/2004 | US20040202704 Transdermal delivery systems and methods |
| 10/14/2004 | US20040202702 Method and composition for the treatment of scars |
| 10/14/2004 | US20040202700 Method for making infection preventive fabric articles suitable for use in ono-invasive biomedical and protective topical applications |
| 10/14/2004 | US20040202699 Textile for weight reduction |
| 10/14/2004 | US20040202698 Drug delivery systems comprising an encapsulated active ingredient |
| 10/14/2004 | US20040202696 solid, oil-insoluble active ingredient dispersed in an oily liquid; preferably palatable to animals, exhibits outstanding stability with water-sensitive active ingredients, and is readily accepted by animals |
| 10/14/2004 | US20040202693 Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem |
| 10/14/2004 | US20040202691 especially a radiation-crosslinked methylene-containing polymer crosslinked with a radiation dose of at least 10,000 rads |
| 10/14/2004 | US20040202687 Ciprofloxacin formulations and methods of making and using the same |
| 10/14/2004 | US20040202682 Self-assembly of nanoparticles at the interface between two fluids; multiple ligands or ligands with multiple functionalities can be attached to the nanoparticles to promote the interfacial segregation and assembly; spherical capsule for drug delivery |
| 10/14/2004 | US20040202681 Process for preparing pharmaceutical formulations using supercritical fluids |
| 10/14/2004 | US20040202680 made of a biodegradable poly( alpha -hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, or a polyanhydride, formed using cationic, anionic, or nonionic detergents the surfaces of which adsorb biologically active macromolecules, such tumor antigens; vaccine delivery |
| 10/14/2004 | US20040202676 using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process |
| 10/14/2004 | US20040202669 Immunogenic compositions containing phospholipid |
| 10/14/2004 | US20040202643 capable of change from insoluble and stable form to soluble and active form upon a change in temperature, pH, chemical composition, concentration, and/or change in shear force acting upon the crystal; capable of releasing their protein activity at a controlled rate |
| 10/14/2004 | US20040202640 Method for topical treatment of scars with rotein Kinase C inhibitors |
| 10/14/2004 | US20040202617 Delivery of opioids through an inhalation route |
| 10/14/2004 | US20040202616 comprises magnesium stearate for improved storage stability; inhalers |
| 10/14/2004 | US20040201117 Coated particles, methods of making and using |
| 10/14/2004 | DE202004012450U1 Delivery unit for administering a medicament into the vaginal cavity of a patient comprises an elongate body with delivery and grip ends, a medicament container, and a piston system |
| 10/14/2004 | DE10315027A1 Kapseln mit verzögerter Freisetzung des Kapselinhaltes zur oralen Verabreichung Sustained-release capsules for oral administration of the capsule content |
| 10/14/2004 | DE10313446A1 Phenazon-haltiges Migränemedikament Phenazone-containing migraine medication |
| 10/14/2004 | DE10106024B4 Verfahren zur Herstellung von Dronabinol Process for preparing dronabinol |
| 10/14/2004 | CA2536612A1 Combination compositions of camptothecins and fluoropyrimidines |
| 10/14/2004 | CA2527130A1 Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| 10/14/2004 | CA2527126A1 Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance |
| 10/14/2004 | CA2521253A1 Pharmaceutical compositions having reduced bitter taste |
| 10/14/2004 | CA2521250A1 Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases |
| 10/14/2004 | CA2521050A1 Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
| 10/14/2004 | CA2520663A1 Disposable, paper-based hospital and operating theater products |
| 10/14/2004 | CA2520600A1 High-intensity sweetener composition and delivery of same |
| 10/14/2004 | CA2520562A1 Dividable tablet |
| 10/14/2004 | CA2520525A1 Ophthalmic drug delivery system using polymer micelle |
| 10/14/2004 | CA2520521A1 Preserved ophthalmic compositions |
| 10/14/2004 | CA2520321A1 Oral extended release compressed tablets of multiparticulates |
| 10/14/2004 | CA2519869A1 Taste-masking vehicle for coated oxazolidinone particles |
| 10/14/2004 | CA2519779A1 A process for preparing a pharmaceutical active ingredient with high specific surface area |
| 10/14/2004 | CA2518903A1 Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
| 10/14/2004 | CA2518872A1 Devices, methods, and compositions to prevent restenosis |
| 10/14/2004 | CA2518533A1 Oral suspension of tegaserod |
| 10/14/2004 | CA2518270A1 Parenteral formulation of mycophenolic acid, a salt or prodrug thereof |
| 10/14/2004 | CA2516429A1 Stable ophthalmic formulation containing an antibiotic and a corticosteroid |
| 10/13/2004 | EP1466968A2 Method and apparatus for encapsulation of biologically-active substances |
| 10/13/2004 | EP1466889A1 Derivatives of venlafaxine and methods of preparing and using the same |
| 10/13/2004 | EP1466649A1 Pharmaceutical composition containing artificial oxygen carrier |
| 10/13/2004 | EP1466641A1 Treatment of pulmonary vasoconstriction and asthma |
| 10/13/2004 | EP1466632A1 Implantable pouch seeded with insulin-producing cells to treat diabetes |
| 10/13/2004 | EP1466631A1 Preparations appropriate for cartilage tissue formation |
| 10/13/2004 | EP1466626A1 Medicinal compositions for improving oral absorption |
| 10/13/2004 | EP1466610A1 Medicinal compositions for nasal absorption |
| 10/13/2004 | EP1466607A1 Compositions for the treatment of primary and metastatic neoplastic diseases using arsenic compounds in combination with all-trans retinoic acid |
| 10/13/2004 | EP1466601A2 Prevention of migraine recurrence |
| 10/13/2004 | EP1466596A1 Novel microsphere and method for production thereof |
| 10/13/2004 | EP1466595A1 Apparatus and process for preparing crystalline particles |
| 10/13/2004 | EP1466594A2 Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| 10/13/2004 | EP1466593A1 Biodegradable injectable implant |
| 10/13/2004 | EP1465926A2 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| 10/13/2004 | EP1465890A1 Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol |
| 10/13/2004 | EP1465865A2 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| 10/13/2004 | EP1465702A1 Device for treating headache |
| 10/13/2004 | EP1465688A1 Bicarbonate-based solutions for dialysis therapies |
| 10/13/2004 | EP1465687A1 Production of a dialysis concentrate from a highly densified concentrate precursor and device for using on the site of dialysis |
| 10/13/2004 | EP1465676A1 Film-forming compositions and methods |
| 10/13/2004 | EP1465665A1 Water-soluble stabilized self-assembled polyelectrolytes |
| 10/13/2004 | EP1465664A1 Stabilized formulations of adenovirus |
| 10/13/2004 | EP1465663A1 Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent |
| 10/13/2004 | EP1465652A2 Povidone-containing carriers for polypeptide growth factors |
| 10/13/2004 | EP1465637A1 25-hydroxy vitamin d3 compositions |
| 10/13/2004 | EP1465636A2 Compositions and methods for enhancing corticosteriod delivery |
| 10/13/2004 | EP1465628A2 Fine particle size pioglitazone |
| 10/13/2004 | EP1465624A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 10/13/2004 | EP1465622A1 Use of ppar activators for the treatment of pulmonary fibrosis |
| 10/13/2004 | EP1465620A2 Novel composition of carvedilol |
| 10/13/2004 | EP1465618A2 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
| 10/13/2004 | EP1465612A1 Controlled release tablets of metformin |
| 10/13/2004 | EP1465608A1 Extended release compositions comprising as active compound venlafaxine hydrochloride |
| 10/13/2004 | EP1465607A1 Pharmaceutical formulations with modified release |
| 10/13/2004 | EP1465606A2 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 10/13/2004 | EP1465605A1 Pravastatin pharmaceutical formulations and methods of their use |
| 10/13/2004 | EP1465604A1 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
| 10/13/2004 | EP1465603A1 Method of producing hollow, microporous particles which are intended, in particular, to be inhaled |
| 10/13/2004 | EP1465602A1 Matrix film tablets for the controlled release of natural mixtures of conjugated estrogen |
| 10/13/2004 | EP1465601A2 A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof |
| 10/13/2004 | EP1465600A1 Particulate compositions comprising a lipophilic liquid |
| 10/13/2004 | EP1465599A1 Liposome composition for delivery of nucleic acid |